; day agents are routinely used to shorten the period of myelo-Ϫ2) followed by infusion of unpurged autologous BM (day suppression following intensive therapy and autologous 0) containing 1.6 ϫ 10 8 total nucleated cells (TNC) and bone marrow transplantation (ABMT).
2-4 Administration of 1.2 ϫ 10 4 colony-forming unit granulocyte-macrophage GM-CSF to humans results in a dose-dependent increase (CFU-GM)/kg patient weight. GM-CSF (5 g/kg) was in blood neutrophils, eosinophils, and, to a lesser extent, administered subcutaneously daily commencing day ϩ1. macrophages and lymphocytes. Dose-related and idiosynOn day 7 she become febrile and tobramycin and piperacilcratic side-effects have been extensively reported. 2, [4] [5] [6] [7] [8] [9] We lin were commenced. On day 9 vancomycin was added and describe two cases of delayed engraftment following because of persistent fevers, amphoterecin was initiated 2 ABMT due to bone marrow (BM) histiocytosis in associdays later. On day 10 she developed weight gain, bilateral ation with capillary leak syndrome, and review the lower leg edema, ascites and bilateral pleural effusions. literature.
These features remained throughout the course of her illness, requiring treatment with regular diuretics and albumin. Full blood count (FBC) on day 10 demonstrated Hb 96g/l, WBC 0.1 ϫ 10 9 /l, absolute neutrophil count (ANC) Ͻ0.03 ϫ 10 9 /l and platelet count 8 ϫ 10 9 /l. At day 14 total bilirubin became elevated and by day 28 was 105 m/l (normal Ͻ20 m/l) (Figure 1a Days after transplant reduced hematopoiesis with extensive involvement by spleen. No histiocytic infiltration was noted in any organ other than the BM. interstitial histiocytes with no evidence of hemophagocytic syndrome or recurrence of HD (Figure 2a ). GM-CSF was then discontinued but the bilirubin continued to rise for a further 2 weeks, peaking at 133 m/l before subsequently Case 2 falling at day 42. Although there was some resolution of the ascites during this period, the ANC fell to Ͻ0.1 ϫ 10 9 /l A 44-year-old man with known hepatic hemangioma and chronic hepatitis B viral infection (HBsAg positive) associated with a further episode of clinical sepsis and the GM-CSF was reinitiated (10 g/kg) on day 42. On day 44 presented 18 months prior to ABMT with bulky stage IVB nodular sclerosing HD involving retroperitoneal, porta hepthe ANC recovered to its prior level, however, there was worsening of the generalized edema. Repeat BM (day 49) atic nodes and liver parenchyma. Staging BM was normal with no evidence of lymphoma. Baseline liver enzymes as demonstrated persistent histiocytic hyperplasia with minimal normal hematopoiesis. Histological analysis, cultures well as bilirubin and serum albumin were normal. He attained CR after six cycles of MOPP/ABVD hybrid and serology were persistently negative for fungus, acid fast bacilli or cytomegalovirus. GM-CSF was again discon-(mechlorethamine, vincrinstine, procarbazine, and prednisone/doxorubicin, bleomycin, vinblastine and tinued on day 52. On day 62 she developed respiratory failure secondary to bilateral diffuse alveolar damage and died dacarbazine). Two months later he progressed with localized bulky intra-abdominal lymphadenopathy. After on day 68. Post-mortem examination demonstrated diffuse pulmonary consolidation, pleural effusions, ascites, and two cycles of mini-BEAM (carmustine, etoposide, cytarabine and melphalan) salvage chemotherapy he achieved a hepatic congestion and zone III necrosis. There were extensive fibrin plugs in glomerular capillaries and pulmonary partial response. Bone marrow performed 2 weeks prior to ABMT was normal with no evidence of HD. The patient vasculature consistent with disseminated intravascular coagulation. Pneumocystis carinii pneumonia with adult subsequently received high-dose etoposide (60 mg/kg; day Ϫ3) and melphalan (180 mg/m 2 , day Ϫ2) followed by respiratory distress syndrome was demonstrated. Histologic examination revealed profound histiocytic infiltration of the infusion of unpurged autologous BM (day 0) containing 3.9 ϫ 10 8 /kg TNC and 1.2 ϫ 10 4 CFU-GM/kg. GM-CSF BM with lymphoid depletion in the lymph nodes and ( Figure 2b ). As there was persistent neutropenia (ANC Ͻ0.1 ϫ 10 9 /l) and fever, GM-CSF (10 g/kg) was recommenced on day 56. On day 58, he developed progressive pleural effusions with hypoxia. He became hypotensive and despite inotropic agents, intubation and dialysis, he died on day 64.
These two cases occurred within 4 months of each other, at the same institution, in the same ward. We reviewed usage of GM-CSF in our unit during this period and for 6 months prior to the reported cases. Sixty patients had received GM-CSF during this time and no other cases of prolonged cytopenia or delayed engraftment with histiocytic infiltrate were identified.
Discussion
The hematopoietic growth factors, G-CSF and GM-CSF, are used extensively following cytotoxic chemotherapy and ABMT. Both factors promote myeloid cell proliferation and maturation resulting in accelerated neutrophil recovery. 2, 4 At low doses of 0.3 to 5 g/kg/day, GM-CSF can cause transient acute leukopenia, dyspnea, low-grade fever, myalgias and fatigue. [5] [6] [7] At doses of 0.3-20 g/kg/day fever, lethargy, myalgia, bone pain, anorexia, weight change, skin eruption, flushing, nausea, vomiting, hypotension and arterial desaturation have been observed. 2, [4] [5] [6] [7] [8] [9] In patients receiving GM-CSF at doses of 20-30 g/kg/day, venous thrombosis, generalized skin eruptions, fluid retention, effusions and pericarditis have also been documented. [5] [6] [7] In this report, we describe two cases of failed engraftment due the post-transplant period. 10 On the basis of this prior observation, we discontinued GM-CSF temporarily in both patients described in this report when hyperbilirubinemia (5 g/kg) was administered subcutaneously daily commencing day ϩ1. Liver function tests and full blood examwas observed. However, unlike our previously reported case, both patients developed capillary leak syndrome in ination were normal prior to autotransplant. On day 4, the bilirubin rose (Figure 1b) . The patient developed fluid addition to liver impairment. Capillary leak syndrome is usually manifested by elevated bilirubin, hypoalbuminemia, retention with third-space accumulation in the form of ascites, pleural effusion, and bilateral leg swelling. Treatpleural effusions, pulmonary interstitial infiltrates, ascites, peripheral edema and can also be associated with pericarment with albumin and diuretics was continued throughout. He had persistent fever from day 6 and was treated with dial effusions and renal dysfunction. 11 As capillary leak syndrome lacks definitive pathological features, the diagtobramycin, piperacillin, vancomycin and amphotericin. On day 23, GM-CSF was discontinued because of increasing nosis is clinical and often difficult to distinguish from the multitude of other factors that can contribute to organ bilirubin. The bilirubin rose to 380 m/l by day 28. As the patient remained neutropenic (and severely thromboimpairment in the post-transplant period. The predominant feature of the capillary leak syndrome described here is cytopenic), G-CSF was initiated, but because of a further rise in the bilirubin, the agent was discontinued on day 35 hyperbilirubinemia and hypoalbuminemia. Indeed, one important differential diagnosis of capillary leak syndrome (Figure 1b) . Liver transaminases remained normal. His course was further complicated by Klebsiella pneumonia is hepatic veno-occlusive disease (VOD). In addition to VOD, drug-induced hepatitis, CMV and hepatosplenic cansepsis, refractory ascites and coagulopathy associated with gastrointestinal bleeding. All investigations for CMV, EBV didiasis are well recognized causes of liver impairment after ABMT. 12 The liver at necropsy in case 1 showed no and fungal infections were negative. CT scans of the chest, abdomen and pelvis showed no evidence of disease recurevidence of VOD, hepatitis, vanishing bile duct syndrome or infection and appropriate serology was negative. The rence. Bone marrow examination on day 56 demonstrated markedly reduced hematopoiesis with extensive histiocytic zone III necrosis observed at necropsy was probably related to the severe refractory hypotension 48 h prior to death. In infiltration and no evidence of hemophagocytosis or HD the second patient, recurrent active hepatitis was unlikely days of therapy, the patient developed a high fever, prominent hepatosplenomegaly, pleural effusion and pancytopas the transaminases were only marginally elevated. Venoocclusive disease, however, cannot be excluded in this latenia. Autopsy demonstrated marked infiltration of macrophages with typical phagocytosis in various organs ter case. The influence of the chronic hepatitis B carrier status of this patient is unknown, although a higher inciincluding liver, spleen and BM. The mechanism of histiocytosis in our patients is dence of mild hepatotoxicity with GM-CSF has been recognized in patients with previous liver disease. 5, 10 unknown but may be related, at least in part, to activation of the monocyte/macrophage system by GM-CSF. GM-CSF is Capillary leak syndrome is usually associated with administration of GM-CSF at high doses 7 and is rarely known to stimulate granulocyte and monocyte production as well as influencing tissue macrophage differentiation, observed at low doses, although concomitant fungal infection, fever and amphotericin administration may predispose proliferation, receptor expression and phagocytosis. Furthermore, it increases the release of monokines which subto its occurrence. [13] [14] [15] Although the syndrome in our two cases commenced prior to pre-emptive antifungal therapy, sequently stimulate the reticuloendothelial system by autocrine, paracrine and systemic effects. Indeed, histithe persistence of this phenomenon may have been related to ongoing GM-CSF and amphotericin therapy.
ocytes can proliferate in the peritoneal cavity in mice treated with high doses of GM-CSF. 27 Lang et al 23 demonImportantly, no systemic fungal infections were identified in either patient. It has been postulated that GM-CSF may strated BM histiocytosis in a patient with Hurler's syndrome following allogeneic bone marrow transplantation be involved in the etiology of this syndrome through alterations in granulocyte adhesion molecule expression, compand treatment with GM-CSF for delayed engraftment. In another patient with Hurler's syndrome, the authors sublement activation, neutrophil oxidative mechanisms and elastase release with subsequent changes in endothelial sequently examined colony growth in culture, with and without the addition of exogenous GM-CSF. They demonadhesive properties. These phenomena may be precipitated by elevated levels of local cytokines such as IL-2 or tumor strated a significant increase in CFU-GM colony growth in BM cultures grown in the presence of GM-CSF. Of partinecrosis factor. [16] [17] [18] [19] [20] Bone marrow histiocytic proliferation can occur in a cular interest, the cytologic examination of the cultured Hurler's syndrome cells revealed an increase in the pronumber of disease states including acquired immunodeficiency syndrome, non-Hodgkin's lymphomas, Hodgkin's portion of abnormal histiocytic colonies. The same authors 28 demonstrated a synergistic action between IL-1, disease, acute myeloid and lymphoblastic leukemias, chronic myeloid leukemia, autoimmune diseases, hemo-IL-6 and basic fibroblast growth factor with GM-CSF to promote histiocyte colony proliferation in marrow obtained phagocytic syndromes associated with viral, bacterial, mycobacterial and protozoal infections. 21 In both patients from a patient with Hurler's syndrome. It is therefore conceivable that the GM-CSF contributes reported here, other recognized causes of histiocytosis such as infection or recurrent HD were not demonstrated.
to the hyperplasia and overstimulation of the mononuclearphagocyte system in this syndrome. [29] [30] [31] [32] [33] It has previously Bone marrow histiocytosis in association with GM-CSF administration has been reported in various clinical setbeen postulated that either the addition of chemotherapy or the presence of lymphoma or both may result in a primary tings.
22-26 Indeed, BM histiocytosis has previously been reported in four patients following intensive therapy and aberrant reaction in reticulo-histiocyte system, possibly triggered by infection. This proliferation may subsequently ABMT. 24 Like our report, Rosenthal and Farhi 24 described delayed engraftment and BM histiocytosis after ABMT, be enhanced by GM-CSF. 25, 34 The causal relationship between BM histiocytosis and however, capillary leak syndrome was not described. Interestingly, although three patients received GM-CSF, one failure to engraft remains unclear. One hypothesis is that the failure of hematopoiesis is primarily the result of inadpatient had not been exposed to this therapy.
Isolated BM histiocytosis has also been reported followequate or defective stem/progenitor cells in the autograft and this suboptimal BM microenvironment may predispose ing conventional-dose chemotherapy. Risti et al 25 described fatal reactive hemophagocytic histiocytosis in two adults to subsequent histiocyte proliferation in the presence of exogenous growth factor. 34 Indeed, we recently performed with non-Hodgkin's lymphoma treated with chemotherapy and GM-CSF. They postulated that GM-CSF either triga retrospective analysis of autografts performed at our institution and it may be of some importance that the progenitor gered or contributed to the reaction of the mononuclear phagocyte system. Wilson et al 22 demonstrated histiocytic cell content of the autografts infused in the two patients are, by these retrospective criteria, considered of 'borderline' infiltration in the BM after 14 days of GM-CSF in a child treated for myelodysplasia (refractory anemia with excess progenitor cell content (ie CFU-GM Ͻ3 ϫ 10 4 /kg).
35
In summary, the two patients described here developed blasts). Interestingly, a BM performed after prior G-CSF therapy did not demonstrate evidence of histiocytes. They graft failure with BM histiocytosis following GM-CSF therapy administered in the post-transplant period. Based on postulated that the histiocytes were the only viable cells in the BM capable of proliferation in response to growth facthe temporal nature of this phenomenon to GM-CSF therapy and the similarity to previously reported cases, we tor stimulation and that the combination of GM-CSF therapy, the underlying myelodysplastic syndrome (MDS), the believe the GM-CSF therapy was a major contributor to the development of the histiocytosis. Furthermore, in presence of systemic infection, and a residual population of BM histiocytes may have led to the development of the association with the histiocytosis, capillary leak syndrome was observed in both patients. 
